



**STATE OF
OHIO**
BOARD OF PHARMACY

COVID-19 Response Efforts - September 10, 2021

HHS Expands Access to COVID-19 Therapeutics

To promote access to therapeutics to treat COVID-19, the Department of Health and Human Services (HHS) amended the [Public Readiness and Emergency Preparedness \(PREP\) Act declaration](#) to provide liability protection to **licensed pharmacists, pharmacy technicians, and pharmacy interns**.

By expanding PREP Act coverage to include these trained professionals for the administration of covered COVID-19 therapeutics, HHS is providing a pathway for increased access to COVID 19 therapeutics, particularly in surge states with rising numbers of COVID-19 cases and in rural areas where access to inpatient and outpatient services may be more limited.

For more information on this change, the Board has developed a guidance document that can be accessed here: www.pharmacy.ohio.gov/MAB

COVID-19 and the Administration of Monoclonal Antibodies and Antiviral Agent by EMS

On August 10, 2021, the U.S. Food and Drug Administration (FDA) revised its previously issued Emergency Use Authorization (EUA) for REGEN-COV®, a co-formulated product that contains casirivimab and imdevimab, for the treatment and post-exposure prophylaxis in select patient populations as outlined in the EUA. On August 27, the NHTSA Office of EMS and the Health and Human Services Office of the Assistant Secretary of Preparedness and Response released the EMS Template Protocol for the COVID-19 Monoclonal Antibody Administration: Treatment and Post-Exposure Prophylaxis of REGEN-COV® ([EMS Template Protocol for COVID-19 Monoclonal Antibody Administration August 2021.pdf](#)) as a resource for EMS medical directors and EMS agencies.

As a reminder, any EMS agency that is administering monoclonal antibodies must update their drug list and protocols (see OAC 4729:5-14-02).

To assist EMS agencies, the Ohio Department of Public Safety issued the following guidance: <https://www.ems.ohio.gov/links/COVID-19/covid-19-mono-clonal-antibodies-viral-agents.pdf>
